Karel Van Damme

A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19

Karel Van Damme (UGent) , Levi Hoste (UGent) , Jozefien Declercq (UGent) , Elisabeth De Leeuw (UGent) , Bastiaan Maes (UGent) , Liesbet Martens (UGent) , Roos Colman (UGent) , Robin Browaeys (UGent) , Cedric Bosteels (UGent) , Stijn Verwaerde (UGent) , et al.

(2023) SCIENCE TRANSLATIONAL MEDICINE. 15(710).

Add to list

Miscellaneous
open access

A Complement Atlas identifies interleukin 6 dependent alternative pathway dysregulation as a key druggable feature of COVID-19

Karel Van Damme (UGent) , Levi Hoste (UGent) , Jozefien Declercq (UGent) , Elisabeth De Leeuw (UGent) , Bastiaan Maes (UGent) , Liesbet Martens (UGent) , Roos Colman (UGent) , Robin Browaeys (UGent) , Cedric Bosteels (UGent) , Stijn Verwaerde (UGent) , et al.

(2023) medRxiv.

Add to list

Journal Article
A1
open access

Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment

Cedric Bosteels (UGent) , Karel Van Damme (UGent) , Elisabeth De Leeuw (UGent) , Jozefien Declercq (UGent) , Bastiaan Maes (UGent) , Victor Bosteels (UGent) , Levi Hoste (UGent) , Leslie Naesens (UGent) , Nincy Debeuf (UGent) , Julie Deckers (UGent) , et al.

(2022) CELL REPORTS MEDICINE. 3(12).

Add to list

Journal Article
A1
open access

Immunosenescence : an unexplored role in glomerulonephritis

Steven Van Laecke (UGent) , Karel Van Damme (UGent) and Amélie Dendooven (UGent)

(2022) CLINICAL & TRANSLATIONAL IMMUNOLOGY. 11(11).

Add to list

Journal Article
A1
open access

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19 : an open-label randomized controlled trial

Elisabeth De Leeuw (UGent) , Karel Van Damme (UGent) , Jozefien Declercq (UGent) , Cedric Bosteels (UGent) , Bastiaan Maes (UGent) , Simon Tavernier (UGent) , Laurent Detalle, Trevor Smart, Sophie Glatt, Nincy Debeuf (UGent) , et al.

(2022) RESPIRATORY RESEARCH. 23(1).

Add to list

Journal Article
A1
open access

TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C

Levi Hoste (UGent) , Lisa Roels (UGent) , Leslie Naesens (UGent) , Victor Bosteels (UGent) , Stijn Vanhee (UGent) , Sam Dupont (UGent) , Cedric Bosteels (UGent) , Robin Browaeys (UGent) , Niels Vandamme (UGent) , Kevin Verstaen (UGent) , et al.

(2022) JOURNAL OF EXPERIMENTAL MEDICINE. 219(2).

Add to list

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID) : a factorial, randomised, controlled trial

Jozefien Declercq (UGent) , Karel Van Damme (UGent) , Elisabeth De Leeuw (UGent) , Bastiaan Maes (UGent) , Cedric Bosteels (UGent) , Simon Tavernier, Stefanie De Buyser (UGent) , Roos Colman (UGent) , Maya Hites, Gil Verschelden, et al.

(2021) LANCET RESPIRATORY MEDICINE. 9(12). p.1427-1438

Add to list

Journal Article
A1
open access

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis

[missing] The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Pere Domingo, Isabel Mur, Gracia María Mateo, Maria del Mar Gutierrez, Virginia Pomar, Natividad de Benito, Noemí Corbacho, Silvia Herrera, Lucia Millan, et al.

(2021) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 326(6). p.499-518

Add to list

Miscellaneous

Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC) : a structured summary of a study protocol for a randomised controlled trial (vol 21, 491, 2020)

Cedric Bosteels (UGent) , Bastiaan Maes (UGent) , Karel Van Damme (UGent) , Elisabeth De Leeuw (UGent) , Jozefien Declercq (UGent) , Anja Delporte, Benedicte Demeyere, Stefanie Vermeersch, Marnik Vuylsteke (UGent) , Joren Willaert, et al.

(2020) TRIALS. 21(1).

Add to list

Miscellaneous

Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID) : a structured summary of a study protocol for a randomised controlled trial (vol 21, 468, 2020)

Bastiaan Maes (UGent) , Cedric Bosteels (UGent) , Elisabeth De Leeuw (UGent) , Jozefien Declercq (UGent) , Karel Van Damme (UGent) , Anja Delporte, Benedicte Demeyere, Stefanie Vermeersch, Marnik Vuylsteke (UGent) , Joren Willaert, et al.

(2020) TRIALS. 21(1).

Academic Bibliography

Karel Van Damme

A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19

A Complement Atlas identifies interleukin 6 dependent alternative pathway dysregulation as a key druggable feature of COVID-19

Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment

Immunosenescence : an unexplored role in glomerulonephritis

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19 : an open-label randomized controlled trial

TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID) : a factorial, randomised, controlled trial

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis

Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC) : a structured summary of a study protocol for a randomised controlled trial (vol 21, 491, 2020)

Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID) : a structured summary of a study protocol for a randomised controlled trial (vol 21, 468, 2020)

Contents

Support

Contact